VERSATILE BIOCONJUGATION PLATFORM

Finally delivering on the promise of antibody-conjugates and protein therapeutics

​

BrickBio's engineered RNA and protein-chemistry platform technology enables custom tailoring of any protein with homogenous, site-specific and site-selective bioconjugation modifications, enabling novel classes of biologics with superior therapeutic windows and characteristics such as half-life, dosage, and efficacy.

Having validated its precise and unrestricted conjugation capabilities through pharmaceutical co-development partnerships, the company is building its internal oncology and immunology pipeline by creating unique antibody and bispecific-conjugates while additionally pioneering spatial protein assembly for Precise Protein Origami™.

Bioconjugation is an effective tool used link multiple proteins or molecules together in order to synergistically enhance their therapeutic effect. In the past, the biotech industry has relied on suboptimal methods, resulting in a staggering number of failed therapeutics due to heterogeneity, lack of stability, or lack of precise control of the conjugation site, amongst other pitfalls.

BrickBio has solved these limitations

We Enable Safer, More Efficacious Therapeutics

BrickBio's precise conjugation technology and control over protein structure open a new world of engineering capabilities, resulting in best-in-class molecules

​

• Proteins with enhanced half-lives, improved specificity, increased activity, mitigated drug-resistance, and overall improved therapeutic windows

• Novel bispecific antibodies distinctly modified at two different sites, completely new avenues for therapeutic advances

• Protein scaffolds with precise functional orientations, also referred to as Spatial Protein Assembly, resulting in therapeutics with unprecedented efficiency​

• Pipeline and pharma co-development efforts leverage our ADC platform as well as our Precise Protein-Origami™ pioneering efforts for novel therapeutics that will revolutionize the oncology and immunology treatment landscapes

BrickBio Advances the Conjugation Status Quo

• Best-in class advancements of genetic code expansion from the Abhishek Chatterjee Lab and internal BrickBio R&D

• Simple and rapid engineering of any protein to contain a bioconjugation handle at any site

• Site-Select Panel driven by proprietary algorithm

• BrickBio has the only solution spanning all aspects of conjugation

  • Precise, unrestricted and efficient site-control of conjugation​

  • Arsenal of stable chemistries for conjugation with improved in vivo stability

  • Multiple compatible chemistries for precise combination

  • Highly efficient Mammalian (CHO) or bacterial expression​​

• Click here for scientific overview

Optimal Therapeutics for Patients

BrickBio ADCs are 100x safer and more efficacious than industry ADCs

RECENT NEWS

OUR TEAM

JOHN BOYCE

CEO, CO-FOUNDER,

TIGER GENE

JAMES ITALIA, PhD

VP, COMMERCIAL

DEVELOPMENT

ABHISHEK CHATTERJEE, PhD

SENIOR ADVISOR &

CHAIRMAN OF SAB

AUDREY WARNER

HEAD OF BUSINESS DEVELOPMENT

BACK TO TOP